Aspira Womens Health (Aspira Womens Health) Days Sales Outstanding : 65.31 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Aspira Womens Health Days Sales Outstanding?

Aspira Womens Health's average Accounts Receivable for the three months ended in Dec. 2023 was $1.52 Mil. Aspira Womens Health's Revenue for the three months ended in Dec. 2023 was $2.13 Mil. Hence, Aspira Womens Health's Days Sales Outstanding for the three months ended in Dec. 2023 was 65.31.

The historical rank and industry rank for Aspira Womens Health's Days Sales Outstanding or its related term are showing as below:

AWH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 21.29 Med: 50.68 Max: 70.2
Current: 59.7

During the past 13 years, Aspira Womens Health's highest Days Sales Outstanding was 70.20. The lowest was 21.29. And the median was 50.68.

AWH's Days Sales Outstanding is ranked better than
65.92% of 223 companies
in the Medical Diagnostics & Research industry
Industry Median: 69.32 vs AWH: 59.70

Aspira Womens Health's Days Sales Outstanding increased from Dec. 2022 (51.83) to Dec. 2023 (65.31).

Aspira Womens Health Days Sales Outstanding Historical Data

The historical data trend for Aspira Womens Health's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aspira Womens Health Days Sales Outstanding Chart

Aspira Womens Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

68.77

70.20

50.69

50.66

53.91

Aspira Womens Health Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															51.83	55.14	58.46	66.43	65.31

Competitive Comparison of Aspira Womens Health's Days Sales Outstanding

For the Diagnostics & Research subindustry, Aspira Womens Health's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aspira Womens Health's Days Sales Outstanding Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's Days Sales Outstanding falls into.

Aspira Womens Health Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Aspira Womens Health's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (1.245	+	1.459)	/	2 )	/	9.154	*	365
=	1.352					/	9.154	*	365
=	53.91

Aspira Womens Health's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (1.59	+	1.459)	/	2 )	/	2.13	*	365 / 4
=	1.5245					/	2.13	*	365 / 4
=	65.31

Aspira Womens Health (NAS:AWH) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Aspira Womens Health Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Aspira Womens Health (Aspira Womens Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (NAS:AWH) » Definitions » Days Sales Outstanding

Comparable Companies

DRIO OCX ENZ BIAF PRE TTOO XGN DMTK SLDX MYNZ TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

N/A

Address

12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738

Website

https://www.aspirawh.com

Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.

Executives

Nicole Sandford	director	12117 BEE CAVES RD BLDG 3, STE 100, AUSTIN TX 78738
Minh Hoang Merchant	officer: General Counsel & Secretary	1210 AVONDALE ROAD, HILLSBOROUGH CA 94010
Torsten Hombeck	officer: Chief Financial Officer	529 W 42ND ST #6V, NEW YORK NY 10036
Celeste Rachelle Fralick	director	2801 MESA ROAD, LUBBOCK TX 79403
Veronica Gh Jordan	director	C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Stefanie L. Cavanaugh	director	1120 S CAPITAL OF TX HWY, BLDG 1, STE 300, AUSTIN TX 78746
Ellen O'connor Vos	director	C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Jack W Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Ryan Thinh Phan	officer: CSO & COO	327 CARLTON AVE, LOS GATOS CA 95032
Jannie Prestridge Herchuk	director	6331 LAVENDALE AVE, DALLAS TX 75230
Winfred Parnell	director	6734 TALMADGE LANE, DALLAS TX 75230
Marlene Mclennan	officer: Interim Chief Financial Office	400 SOUTH AUSTRALIAN AVENUE, SUITE 800, WEST PALM BEACH FL 33401
Ruby Sharma	director	24 ARNOLD DRIVE, PRINCETON JCT. NJ 08550
Robert D Auerbach	director	C/O THE COOPER COMPANIES, INC., SUITE 590, PLEASANTON CA 94588
Valerie Barber Palmieri	director, officer: President and CEO	63 INDIAN LEDGE RD., MONROE CT 06468